United Therapeutics (UTHR) EBIAT (2009 - 2026)

United Therapeutics has disclosed EBIAT across 18 years of filings, most recently posting $274.9 million for Q1 2026.

• EBIAT for Q1 2026 came in at $274.9 million, down 14.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 6.34% YoY), and the FY2025 annual result was $1.3 billion, up 11.68% from the prior year.
• EBIAT came in at $274.9 million for Q1 2026 at United Therapeutics, down from $364.3 million in the prior quarter.
• In the past five years, EBIAT ranged from a high of $364.3 million in Q4 2025 to a low of $116.0 million in Q2 2022.
• The 5-year median for EBIAT is $274.9 million (2026), against an average of $265.7 million.
• Peak annual rise in EBIAT reached 747.7% in 2022, while the deepest fall reached 32.79% in 2022.
• United Therapeutics' EBIAT stood at $132.1 million in 2022, then soared by 64.35% to $217.1 million in 2023, then soared by 38.78% to $301.3 million in 2024, then rose by 20.91% to $364.3 million in 2025, then decreased by 24.54% to $274.9 million in 2026.
• The last three EBIAT figures came in at $274.9 million (Q1 2026), $364.3 million (Q4 2025), and $338.7 million (Q3 2025), per Business Quant data.